December 19, 2018Open Access

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects. (Funded by R ClinicalTrials.gov number, NCT01526135 ; EudraCT number, 2011-002026-52 .).

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Key Points

Abstract

Cite This Study